Inlyta (axitinib) / Pfizer 
Welcome,         Profile    Billing    Logout  
 113 Diseases   87 Trials   87 Trials   3938 News 
53 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Inlyta (axitinib) / Pfizer
KEYNOTE 426, NCT02853331 / 2016-000588-17: Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)

Checkmark Long-term follow-up data from KEYNOTE-426 trial in combination with axitinib for RCC at ASCO 2021
Jun 2021 - Jun 2021: Long-term follow-up data from KEYNOTE-426 trial in combination with axitinib for RCC at ASCO 2021
Checkmark Long term follow-up data from KEYNOTE-426 trial in combination with Inlyta for RCC
May 2020 - May 2020: Long term follow-up data from KEYNOTE-426 trial in combination with Inlyta for RCC
Checkmark KEYNOTE-426 trial in combination with Inlyta in 1L advanced RCC at ASCO-GU 2019
More
Active, not recruiting
3
861
NA
Pembrolizumab, MK-3475, KEYTRUDA®, Axitinib, INLYTA®, Sunitinib, SUTENT®
Merck Sharp & Dohme LLC
Renal Cell Carcinoma
10/18
12/25
AxiPRO, NCT04764487: A Web-mediated Follow-up With the Web-application KidneyPRO Versus Standard Follow-up for Patients With Advanced Renal Cell Carcinoma Treated With Axitinib/Pembrolizumab in First Line

Recruiting
3
178
Europe
KidneyPRO, web-application, standard follow-up
Weprom, Pfizer, FLGXPL
Renal Cell Carcinoma Metastatic
06/23
06/25
JAVELIN Renal 101, NCT02684006 / 2015-002429-20: A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer

Checkmark Data from JAVELIN Renal 101 trial in combination with axitinib for IL RCC at ESMO 2019
Sep 2019 - Oct 2019: Data from JAVELIN Renal 101 trial in combination with axitinib for IL RCC at ESMO 2019
Checkmark JAVELIN Renal 101 trial in 1L mRCC
Feb 2019 - Feb 2019: JAVELIN Renal 101 trial in 1L mRCC
Checkmark Data presentation from JAVELIN Renal 101 trial in combination with Inlyta for 1L RCC at ESMO 2018
More
Completed
3
886
Europe, Canada, Japan, US, RoW
Avelumab (MSB0010718C), Axitinib (AG-013736), Inlyta, Sunitinib, Sutent
Pfizer
Renal Cell Cancer
08/23
06/24
PREPARE, NCT03013946 / 2016-000399-28: Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy

Recruiting
3
430
Europe
Concomitant coaching
AIO-Studien-gGmbH, Pfizer, Crolll Gmbh
Renal Cell Carcinoma, Metastatic, Renal Cell Cancer, Recurrent
01/24
07/24
NCT05059522 / 2021-002457-29: Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Active, not recruiting
3
62
Europe, Canada, Japan, US, RoW
Avelumab, Lorlatanib, Talazoparib, Pemetrexed, Axitinib, CMP 001, Utomilumab, PF04518600
Pfizer
Advanced Malignancies, NSCLC, Ovarian Cancer, Urothelial Cancer, Solid Tumors
09/26
09/26
NCT01744249 / 2011-001550-29: Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas

Active, not recruiting
2/3
255
Europe
Axitinib, Sandostatin LAR, Placebo
Grupo Espanol de Tumores Neuroendocrinos, Pfizer
Neuroendocrine Tumors, Advanced Cancer
08/21
10/21
FRUSICA-2, NCT05522231: Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma

Recruiting
2/3
264
RoW
fruquintinib+sintilimab, HMPL-013 + IBI308, axitinib / everolimus, fruquintinib, HMPL-013
Hutchison Medipharma Limited
Advanced Renal Cell Carcinoma
11/24
03/25
2014-003227-21: Phase II study on Inlyta® (axitinib) in recurrent and/or metastatic salivary gland cancers (SGCs) of the upper aerodigestive tract Studio di fase 2 con Inlyta® (Axitinib) nel tumore delle ghiandole salivari del tratto aerodigestivo superiore, recidivato e/o metastatico

Ongoing
2
26
Europe
Axitinib, AG-013736, Coated tablet, Inlyta
Fondazione IRCCS Istituto Nazionale dei Tumori Milano, Fondazione IRCCS Istituto Nazionale dei Tumori Milano, Pfizer Italy
recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract tumore delle ghiandole salivari del tratto aerodigestivo superiore, recidivato e/o metastatico, recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract tumore delle ghiandole salivari del tratto aerodigestivo superiore, recidivato e/o metastatico, Diseases [C] - Cancer [C04]
 
 
2011-001793-26: A Phase II Trial of Metformin and Axitinib in BRAF Mutated Advanced Melanoma (MAXIM)

Ongoing
2
48
Europe
Axitinib, Metformin, (AG-013736), Metformin, Metformin
Royal Marsden Hospital, Pfizer
Advanced BRAF mutant melanoma
 
 
2014-003811-13: Improving treatment selection in patients with cancer using a personalized screening test Het beter selecteren van een behandeling voor patiënten met kanker met behulp van een gepersonaliseerde screening test.

Ongoing
2
70
Europe
Palbociclib, Axitinib, Selumetinib, Gefitinib, PD-0332991, PF-04449913, PF-05212384, AG-013736, AZD6244, AZD2014, AZD5363, ZD1839, Capsule, hard, Tablet, Lyophilisate for solution for infusion, Capsule, Inlyta, Iressa
Antoni van Leeuwenhoek - Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital - Netherlands Cancer Institute, Pfizer Inc., AstraZeneca
Colorectal cancer and non-small cell lung cancer colorectaal carcinoom en niet-kleincellig longkanker, colorectal cancer and lung cancer Dikkedarmkanker en longkanker, Diseases [C] - Cancer [C04]
 
 
2017-000619-17: A study to see how effective the drug (Axitinib) is at preventing cancer cells from growing and to see if this means that patients with kidney cancer require less extensive surgery.

Not yet recruiting
2
20
Europe
Inlyta, Film-coated tablet, Inlyta
Common Services Agency (CSA), Pfizer
Venous tumour thrombus in clear cell renal cell cancer with venous invasion, kidney cancer, Diseases [C] - Cancer [C04]
 
 
NCT02636725: Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas

Completed
2
33
US
Axitinib, Inlyta, Pembrolizumab, MK-3475, Keytruda
Jonathan Trent, MD, PhD, Merck Sharp & Dohme LLC, Pfizer
Alveolar Soft Part Sarcoma, Soft Tissue Sarcomas
05/18
03/23
2017-004048-38: Avelumab in combination with Axitinib in patients with advanced Thymic tumours Avelumab in combinazione con Axitinib in pazienti con carcinomi timici in stadio avanzato

Ongoing
2
33
Europe
Avelumab, INLYTA, [MSB0010718C], [AG-013736], Solution for infusion, Coated tablet, INLYTA - 5 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (ALU/ALU) 56 COMPRESSE
ISTITUTO EUROPEO DI ONCOLOGIA, PFIZER S.r.l
Histologically confirmed advanced Thymoma B3 or Thymic carcinoma inoperable (Masaoka Stage IIIb or IV). Pazienti affetti da timoma avanzato B3 o carcinoma timico inoperabile (stadio IIIb o IV), advanced thymic carcinoma carcinoma timico avanzato, Diseases [C] - Cancer [C04]
 
 
2018-003998-96: A Phase II, single arm Study of avelumab In combination with Axitinib in Patients With unresectable/metastatic Gastrointestinal Stromal Tumor after failure of standard therapy - AXAGIST

Not yet recruiting
2
58
Europe
Axitinib, AVELUMAB, [63539-026], [EU/1/17/1214/001], Coated tablet, Concentrate for solution for infusion, Inlyta, Bavencio
Centrum Onkologii – Instytut im. Marii Skłodowskiej - Curie, Maria Sklodowska-Curie National Research Institute of Oncology (MSCNRIO), Centrum Onkologii – Instytut im. Marii Skłodowskiej – Curie, Pfizer Polska, Maria Sklodowska-Curie National Research Istitute of Oncology, Pfizer Ltd
GIST - unresectable/metastatic Gastrointestinal Stromal Tumor after failure of standard therapy, Gastrointestinal Stromal Tumor (GIST), Diseases [C] - Cancer [C04]
 
 
SuAx, NCT03592199: Biomarker Study of Pts With Metastatic ccRCC Undergoing Sequential Therapy With 1st Line Sunitinib and 2nd Line Axitinib

Active, not recruiting
2
7
RoW
Sunitinib, Axitinib
Instituto do Cancer do Estado de São Paulo, Pfizer
Clear Cell Renal Cell Carcinoma
12/19
12/22
2019-004771-40: ProTargetA Danish Nationwide Clinical Trial on Targeted Anti-Cancer Treatment based on Genomic Profiling

Not yet recruiting
2
300
Europe
Zejula, Capsule, hard, Concentrate and solvent for solution for infusion, Tablet, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Alcensa, Tecentriq, Cotellic, Zelboraf, Herceptin, Perjeta, Kadcyla, Erivedge, Bavencio, Inlyta, Zejula, pemazyre, Retsevmo
Rigshospitalet, Roche, Pfizer
Eligible patients will have an advanced malignant disease for which standard treatment options are no longer available or feasible and acceptable performance status and organ function. Patienter med fremskreden og/eller metastatisk solid tumor, som har oplevet progression under standardbehandling, eller som er intolerante over for standardbehandling, Patients with advanced cancer without curative therapeutic options Patienter med fremskreden kræft uden mulighed for kurativ behandling, Diseases [C] - Cancer [C04]
 
 
2019-004098-23: Phase II study of avelumab plus intermittent axitinib in previously untreated patients with metastatic renal cell carcinoma (Tide-A study). Studio di fase II sull’uso in prima linea di avelumab in combinazione con axitinib intermittente in pazienti con carcinoma renale metastatico (studio Tide-A)

Ongoing
2
75
Europe
Inlyta, Avelumab, [Axitinib], [axitinib], [Avelumab], Film-coated tablet, Solution for infusion, INLYTA - 1 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (ALU/ALU) 56 COMPRESSE, INLYTA - 3 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (ALLUMINIO/ALLUMINIO) 56 COMPRESSE, INLYTA - 5 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (ALU/ALU) 56 COMPRESSE
CONSORZIO ONCOTECH, Pfizer
metastatic renal cell carcinoma Carcinoma renale metastatico, metastatic renal cell carcinoma Carcinoma renale metastatico, Diseases [C] - Cancer [C04]
 
 
NCT01263769: Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC)

Checkmark ASCO-GU 2014
Jan 2014 - Jan 2014: ASCO-GU 2014
Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Completed
2
39
US
Axitinib, AG-013736
M.D. Anderson Cancer Center, Pfizer
Kidney Cancer
02/21
06/23
2022-001150-35: Phase II study of axitinib intensification plus nivolumab compared to nivolumab alone after induction with nivolumab plus ipilimumab in mRCC patients without previous complete response (AxIn study). Studio di fase II sull’intensificazione di axitinib più nivolumab rispetto a nivolumab da solo dopo l’induzione con nivolumab più ipilimumab in pazienti con mRCC senza una precedente risposta completa (studio AxIn).

Not yet recruiting
2
118
Europe
Inlyta, [Axitinib], Film-coated tablet, Inlyta 3 mg, Inlyta 5MG, inlyta 1 mg
CONSORZIO ONCOTECH, Pfizer S.r.L
Metastatic renal cell carcinoma Carcinoma a cellule renali metastatico, Metastatic renal cell carcinoma Carcinoma a cellule renali metastatico, Diseases [C] - Cancer [C04]
 
 
NEOAVAX, NCT03341845: Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC

Checkmark Data from NeoAvAx trial in combination with Inlyta for RCC
Feb 2022 - Feb 2022: Data from NeoAvAx trial in combination with Inlyta for RCC
Recruiting
2
40
Europe
Axitinib, Avelumab
The Netherlands Cancer Institute, Pfizer
Renal Cell Carcinoma
01/23
01/25
Javelin Medley VEGF, NCT03472560 / 2017-004345-24: A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer

Terminated
2
61
Europe, US, RoW
Avelumab (MSB0010718C), Bavencio, Axitinib (AG-013736), Inlyta
Pfizer
Non-Small Cell Lung Cancer, Urothelial Cancer
02/23
02/23
2021-006430-39: A Study of Immune Checkpoint Inhibitor Combinations with Axitinib in Patients with Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma Un estudio de combinaciones inhibidoras de puntos de control inmunitario con Axitinib en pacientes con carcinoma de células renales no tratado previamente localmente avanzado no resectable o metastásico

Not yet recruiting
2
210
Europe
tiragolumab, PD1-LAG3, Pembrolizumab, RO7092284/F03-01, RO7247669/F01-01, RO7223188, Concentrate for solution for infusion, Solution for infusion, Film-coated tablet, INLYTA®, KEYTRUDA®
Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd, F.Hoffmann-La Roche Ltd, F.Hoffmann-La Roche Ltd
Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma Carcinoma de células renales localmente avanzado no resectable o carcinoma de células renales metastásico, Clear Cell Renal cell carcinoma (RCC), is the most common type of kidney cancer El carcinoma de células renales (CCR) de células claras es el tipo de cáncer de riñón más común, Diseases [C] - Cancer [C04]
 
 
NCT05420220: Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer

Recruiting
2
54
RoW
KN046 (Recombinant Humanized PD-L1/CTLA-4 Bispecific Single Domain Antibody Fc Fusion Protein Injection), Axitinib
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Advanced Non-small Cell Lung Cancer
05/27
12/27
TIDE-A, NCT04698213: Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma

Recruiting
2
75
Europe
Axitinib Oral Tablet, Avelumab
Consorzio Oncotech, Clinical Research Technology S.r.l.
Renal Carcinoma Metastatic
09/23
10/24
NCT04493203 / 2005-001438-34: Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma

Active, not recruiting
2
31
US
Nivolumab, Opdivo, AG013736, Axitinib, INLYTA
Yana Najjar, Pfizer, Bristol-Myers Squibb
Advanced Melanoma, Unresectable Melanoma
04/24
02/29
NCT03839498: Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma

Recruiting
2
25
US
Axitinib, AG-013736
Columbia University, Pfizer
Pheochromocytoma, Paraganglioma
12/23
01/24
ProTarget, NCT04341181: - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling

Recruiting
2
300
Europe
Alectinib, Alecensa, Atezolizumab, Tecentriq, Avelumab, Bavencio, Axitinib, Inlyta, Erlotinib, Tarceva, Vemurafenib plus Cobimetinib (combination), Zelboraf plus Cotellic (combination), Trastuzumab plus Pertuzumab (combination), Herceptin plus Perjeta (combination), Trastuzumab emtansine, Kadcyla, Vismodegib, Erivedge, Niraparib, Zejula
Ulrik Lassen, Roche Pharma AG, Pfizer, GlaxoSmithKline
Cancer, Tumors, Neoplasms, Neoplasia
04/24
04/25
NCT05256472: A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma

Recruiting
2
70
RoW
AK104, axitinib
Akeso
Renal Cell Carcinoma, First-line Treatment
07/24
12/25
NCT04996823: Axitinib + Ipilimumab in Advanced Melanoma

Recruiting
2
25
US
Ipilimumab, Yervoy, Axitinib, Inlyta
H. Lee Moffitt Cancer Center and Research Institute, Pfizer
Melanoma
08/24
08/27
NCT04370509: Pembrolizumab With or Without Axitinib for Treatment of Locally Advanced or Metastatic Clear Cell Kidney Cancer in Patients Undergoing Surgery

Active, not recruiting
2
6
US
Axitinib (VEGF-TKI), AG-013736, AG013736, Inlyta, Cytoreductive Nephrectomy (CN), Cytoreduction, Nephrectomy, Metastasectomy (MET), Metastasectomy, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
University of California, San Francisco, Merck Sharp & Dohme LLC
Metastatic Clear Cell Renal Cell Carcinoma, Recurrent Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Clear Cell Renal Cell Carcinoma
09/24
09/25
NCT05805501: A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

Recruiting
2
210
Europe, US, RoW
Tobemstomig, RO7247669, Tiragolumab, Pembrolizumab, Keytruda, Axitinib, Inlyta
Hoffmann-La Roche
Renal Cell Carcinoma
09/24
03/26
NCT02912572: Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer

Active, not recruiting
2
106
US
Avelumab, Talazoparib, Axitinib
Dana-Farber Cancer Institute, Pfizer
Metastatic Endometrial Cancer
11/23
11/26
NCT05738694: Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma

Recruiting
2
246
RoW
Axitinib plus Toripalimab, nephrectomy
ZHOU FANGJIAN, Pfizer
Renal Cell Carcinoma, Neoadjuvant
07/25
03/26
CAPTUR, NCT03297606: Canadian Profiling and Targeted Agent Utilization Trial

Recruiting
2
720
Canada
Olaparib, Dasatinib, Nivolumab plus Ipilimumab, Axitinib, Bosutinib, Crizotinib, Palbociclib, Sunitinib, Temsirolimus, Erlotinib, Trastuzumab plus Pertuzumab, Vemurafenib plus Cobimetinib, Vismodegib, Tucatinib
Canadian Cancer Trials Group, AstraZeneca, Bristol-Myers Squibb, Hoffmann-La Roche, Pfizer, Seagen Inc.
Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
01/26
01/27
AxIn, NCT05817903: Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients

Recruiting
2
118
Europe
Axitinib, Inlyta, Nivolumab
Consorzio Oncotech, Pfizer
Metastatic Renal Cell Carcinoma
04/26
04/27
NCT05384496: Axitinib and Nivolumab for the Treatment of Mucosal Melanoma

Recruiting
2
20
US
Nivolumab and/or Ipilimumab, Stereotactic Body Radiation Therapy (SBRT), axitinib
Memorial Sloan Kettering Cancer Center, Pfizer
Mucosal Melanoma
05/26
05/26
APART, NCT05176288: Avelumab, Palbociclib and Axitinib in Advanced RCC

Withdrawn
2
25
NA
Axitinib, Inlyta, Palbociclib, Ibrance, Avelumab, Bavencio
Bradley A. McGregor, MD, Pfizer
Advanced Clear Cell Renal Cell Carcinoma
08/26
08/27
Strata PATH, NCT05097599: ™ (Precision Indications for Approved Therapies)

Active, not recruiting
2
700
US
lorlatinib, encorafenib + binimetinib, talazoparib, sacituzumab govitecan, axitinib
Strata Oncology, Merck Sharp & Dohme LLC, Pfizer, Gilead Sciences
Cancer, Advanced Solid Tumor
11/26
11/29
DRUP, NCT02925234 / 2015-004398-33: The Drug Rediscovery Protocol ( Trial)

Recruiting
2
1550
Europe
Panitumumab, Vectibix, Olaparib, Lynparza, Dabrafenib, Tafinlar, Nilotinib, Tasigna, Trametinib, Mekinist, Erlotinib, Tarceva, Trastuzumab and Pertuzumab (combination treatment), Herceptin + Perjeta, Vemurafenib and Cobimetinib (combination treatment), Zelboraf + Cotellic, Vismodegib, Erivedge, Regorafenib, Stivarga, Nivolumab, Opdivo, Afatinib, Giotrif, Dabrafenib and trametinib, Tafinlar and Mekinist, Ribociclib, Kisqali, Lenvatinib, Lenvima, Pembrolizumab, Keytruda, Durvalumab, MEDI4736, Rucaparib, Rubraca, Axitinib, Inlyta, Palbociclib, Ibrance, Crizotinib, Xalkori, Sunitinib, Sutent, Cabozantinib, Cabometyx, Abemaciclib, Verzenios, Alectinib, Alecensa, Atezolizumab and Bevacizumab, Tecentriq and Avastin, Ipilimumab and nivolumab, Yervoy and Opdivo, Entrectinib, Rozlytrek, Talazoparib, Talzenna, Dacomitinib, Vizimpro, Lorlatinib, Lorviqua, Erdafitinib, Balversa, Alpelisib, Piqray, Niraparib, Zejula, Pemigatinib, Pemazyre, Selpercatinib, Retsevmo, Tepotinib, Tepmetko
The Netherlands Cancer Institute, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Novartis, Roche Pharma AG, Merck Sharp & Dohme LLC, Boehringer Ingelheim, Ipsen, Eisai Inc., Pfizer, Clovis Oncology - Pharma and, Eli Lilly and Company, Janssen, LP, GlaxoSmithKline, Incyte Corporation, Dutch Cancer Society, Stelvio for Life
Cancer, Tumors, Neoplasm, Neoplasia
09/27
12/27
NCT02535533: SLM + Axitinib for Clear Cell RCC

Active, not recruiting
1/2
46
US
Selenomethionine (SLM), Axitinib
Yousef Zakharia, Pfizer
Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC)
08/23
05/26
LANDSCAPE 1011, NCT04585815 / 2020-002829-28: Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

Active, not recruiting
1/2
34
Europe, US, RoW
Sasanlimab Prefilled syringe, Encorafenib, Binimetinib, Sasanlimab, Axitinib, SEA-TGT
Pfizer
Carcinoma, Non-Small-Cell Lung
05/23
06/24
NCT05949632: A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors

Active, not recruiting
1/2
5
Europe
INCB099280, axitinib
Incyte Corporation
Advanced Solid Tumors
12/26
12/27
NCT04688658: Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma

Recruiting
1/2
42
US
Nivolumab, Opdivo, AG013736, Duvelisib, Copiktra
John Kirkwood, Secura Bio, Inc., Bristol-Myers Squibb
Unresectable Melanoma
04/28
10/29
NCT04640545: A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma

Recruiting
1
88
RoW
LBL-007, Toripalimab, Axitinib Tablets
Nanjing Leads Biolabs Co.,Ltd
Advanced Melanoma
08/24
12/24
PIVOT IO 011, NCT04540705: A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread

Completed
1
30
Europe, Canada, US, RoW
Nivolumab, OPDIVO, Axitinib, INLYTA, Cabozantinib, Cabometyx
Bristol-Myers Squibb, Nektar Therapeutics
Renal Cell Carcinoma
01/24
01/24
NCT04458259: Study of PF-07265807 in Participants With Metastatic Solid Tumors.

Active, not recruiting
1
67
Europe, Canada, Japan, US, RoW
PF-07265807, ARRY-067, Sasanlimab, PF-06801591; RN-888, Axitinib, AG-013736; Inlyta
Pfizer
Neoplasm Metastasis
06/24
06/24
TACE-Ax-HCQ, NCT04873895: TACE Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Colorectal Cancer (CRC)

Terminated
1
5
US
Axitinib 5 MG, Hydroxychloroquine Pill, trans arterial chemoembolization
Abramson Cancer Center at Penn Medicine, Pfizer
Colorectal Neoplasms Malignant
04/24
04/24
NCT04522323: A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma

Recruiting
1
179
Europe, US, RoW
MEDI5752, Axitinib, Lenvatinib
MedImmune LLC
Advanced Renal Cell Carcinoma
08/27
08/27
MK-3475A-C18, NCT05017012: A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of MK-3475A (Pembrolizumab Formulated With MK-5180) In Advanced Solid Tumors

Active, not recruiting
1
72
Europe, Japan, RoW
MK-3475A, Pembrolizumab, Keytruda, MK-3475, Pemetrexed, Alimta, Carboplatin, Paclitaxel, Taxol, Nab-paclitaxel, Albumin-bound paclitaxel, Axitinib, Cisplatin, Platinol-AQ
Merck Sharp & Dohme LLC
Advanced or Metastatic Solid Tumors
09/26
09/26
NCT01473043: Clinical Study With Axitinib In Advanced Kidney Cancer, Who Have Failed First Line Treatment

No Longer Available
N/A
Canada, RoW
Axitinib, AG-013736
Pfizer
Renal Cell Carcinoma
03/14
03/14
NCT02354612: Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial

No Longer Available
N/A
US
TRC105, Chimeric Antibody (TRC105) to CD105, Bevacizumab, Avastin, Axitinib, Inlyta, Pazopanib, Votrient, Capecitabine, Xeloda
Tracon Pharmaceuticals Inc.
Solid Tumors
 
 
A4061008, NCT00828919 / 2005-000051-15: Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials

Completed
N/A
52
Europe, Japan, US, RoW
axitinib, AG-013736, crizotinib, PF-02341066
Pfizer
Solid Tumors
08/23
08/23
NCT05394493: An Observational Chart Review Study To Describe The Real-World Outcomes And Use Of Avelumab In Combination With Axitinib For Treatment Of Patients With aRCC In The UK

Completed
N/A
130
Europe
avelumab, axitinib
Pfizer
Advanced Renal Cell Carcinoma
08/23
08/23

Download Options